CAMBRIDGE, Mass.–(BUSINESS WIRE)–Quiver Bioscience (“Quiver”) and QurAlis Corporation (“QurAlis”), today announced that the companies have entered into a research collaboration to advance a novel gene-targeted therapeutic approach for the treatment of Fragile X syndrome (FXS). The goal of the collaboration is to combine Quiver’s unique “Genomic Positioning System” (GPS) drug discovery platform with QurAlis’ expertise in developing next-generation precision medicines for neurodegenerative and neurological diseases to build a foundational data package in support of advancing a potentially transformative therapeutic for FXS.
[Read more…] about Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X SyndromeBridging the Gap Between Science and Business
